Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Goldberg

MOHS-Micrographic Surgery Hackensack, NJ Medical Doctor

NPI 1528001583 CMS profile 250516

20 Prospect Ave Ste 702, Hackensack, NJ 07601

Open in the dashboard

General payments

$820,266

314 records reported · program years 2019–2025

Research payments

$55,133

Paid to them · 10 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$800,966 paid to institutions, not to them · program years 2019–2025

Through program year 2025, David Goldberg of Hackensack, NJ is reported in the CMS Open Payments database as having received $820,266 across 314 general payments and $55,133 in research payments paid to them. Separately, studies naming them as principal investigator received $800,966 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $87,674 55
2024 General $171,197 35
2024 Research $1,713 6
2023 General $219,433 40
2022 General $18,830 51
2022 Research $20,420 1
2021 General $39,408 43
2021 Research $30,000 2
2020 General $88,166 21
2019 General $195,558 69
2019 Research $3,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Goldberg
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to David Goldberg were reported at $87,674. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year David Goldberg MOHS-Micrographic Surgery median Middle half National median
2019 $195,558 $316 $106–$785 $163
2020 $88,166 $162 $68–$412 $114
2021 $39,408 $243 $87–$654 $132
2022 $18,830 $300 $102–$887 $149
2023 $219,433 $364 $125–$1,010 $160
2024 $171,197 $445 $142–$1,108 $164
2025 $87,674 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $372,331 41 payments
  2. Galderma Laboratories, L.P. $119,502 28 payments
  3. Sensus Healthcare, Inc. $91,597 4 payments
  4. Musculoskeletal Transplant Foundation Inc. $85,691 20 payments
  5. Lumenis, Inc $34,716 2 payments
  6. Sun Pharmaceutical Industries Inc. $27,921 28 payments
  7. Allergan Inc. $19,401 32 payments
  8. Biofrontera Inc. $12,079 9 payments
  9. Regeneron Pharmaceuticals, Inc. $10,250 8 payments
  10. Verrica Pharmaceuticals Inc. $7,767 3 payments
  11. Other $39,011 139 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $473,900 14 payments
  2. Consulting Fee $165,494 55 payments
  3. Honoraria $91,000 2 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $42,636 7 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $21,970 5 payments
  6. Food and Beverage $9,358 209 payments
  7. Travel and Lodging $7,321 20 payments
  8. Education $7,000 1 payment
  9. Long term medical supply or device loan $1,587 1 payment
Products named General payments · program years 2019–2025
  1. BOTOX $42,913 11 payments
  2. Leqselvi $24,500 18 payments
  3. LIBTAYO $13,526 14 payments
  4. BF-RhodoLED $12,064 8 payments
  5. AMELUZ $10,512 3 payments
  6. YCANTH $7,767 3 payments
  7. SKYRIZI $7,500 1 payment
  8. RhodoLED XL $7,500 1 payment
  9. DYSPORT $3,515 3 payments
  10. Winlevi $3,203 7 payments
  11. Other $21,448 195 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Musculoskeletal Transplant Foundation Inc. $50,420 3 payments
  2. Sensus Healthcare, Inc. $3,000 1 payment
  3. AbbVie, Inc. $1,713 6 payments

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

185

Median for Dermatology: 534

Drug cost

$2,078

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Triamcinolone Acetonide Generic 64 $1,015
Mupirocin Generic 82 $651
Doxycycline Hyclate Generic 14 $290
Hydrocortisone Generic 25 $123

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$239,976

Medicare's payments for the services billed

Medicare patients

336

Average age 76

Services billed

1,456

137 women, 199 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 46%
Ischemic heart disease 35%
Diabetes 27%
Cancer 21%
Atrial fibrillation 18%
Chronic kidney disease 18%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
YCANTH
  • VERRICA PHARMACEUTICALS INC. $7,750
$7,750 — —
SKYRIZI
  • AbbVie, Inc. $7,500
$7,500 — —
AMELUZ
  • Biofrontera Inc. $4,000
$4,000 — —
BOTOX
  • AbbVie, Inc. $110
$110 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $103
$103 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

324 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record